SLA

Summary

SLA (Src like adaptor, HGNC:10902) is a protein-coding gene on chromosome 8q24.22, encoding Src-like-adapter (Q13239). Adapter protein, which negatively regulates T-cell receptor (TCR) signaling.

Predicted to enable epidermal growth factor receptor binding activity and phosphotyrosine residue binding activity. Predicted to be involved in regulation of MAPK cascade and signal transduction. Predicted to be located in cytosol. Predicted to be part of COP9 signalosome. Predicted to be active in cytoplasm; nucleoplasm; and plasma membrane.

Source: NCBI Gene 6503 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 150 total — 6 pathogenic, 2 likely-pathogenic
• MANE Select transcript: NM_001045556

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10902
Approved symbol	SLA
Name	Src like adaptor
Location	8q24.22
Locus type	gene with protein product
Status	Approved
Aliases	SLA1, SLAP-1, hSLAP, SLAP
Ensembl gene	ENSG00000155926
Ensembl biotype	protein_coding
OMIM	601099
Entrez	6503

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 15 protein_coding, 6 protein_coding_CDS_not_defined, 5 retained_intron, 1 nonsense_mediated_decay

ENST00000338087, ENST00000395352, ENST00000427060, ENST00000517549, ENST00000517615, ENST00000517648, ENST00000517932, ENST00000518565, ENST00000518594, ENST00000519341, ENST00000519504, ENST00000519558, ENST00000519747, ENST00000520106, ENST00000521302, ENST00000521823, ENST00000522002, ENST00000522119, ENST00000522432, ENST00000522946, ENST00000523224, ENST00000523610, ENST00000524345, ENST00000953118, ENST00000953119, ENST00000953120, ENST00000953121

RefSeq mRNA: 5 — MANE Select: NM_001045556 NM_001045556, NM_001045557, NM_001282964, NM_001282965, NM_006748

CCDS: CCDS47922, CCDS47923, CCDS6370, CCDS64977, CCDS64978

Canonical transcript exons

ENST00000338087 — 9 exons

Exon	Start	End
ENSE00001167875	133039998	133040130
ENSE00001167888	133044984	133045115
ENSE00001343977	133036728	133038737
ENSE00001369746	133074853	133075130
ENSE00002139856	133102553	133102602
ENSE00003552270	133050816	133050915
ENSE00003589612	133047830	133047933
ENSE00003628374	133049902	133049988
ENSE00003650420	133060100	133060200

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 99.28.

FANTOM5 (CAGE): breadth broad, TPM avg 16.3379 / max 1136.1670, expressed in 561 samples.

FANTOM5 promoters (18 alternative TSS)

Promoter ID	TPM avg	Samples expressed
95126	6.1288	468
95124	4.0440	448
95123	1.2769	309
95125	1.2298	346
95118	0.7549	151
95133	0.6798	23
95119	0.5974	154
95120	0.4508	149
95117	0.4239	108
95127	0.3688	193

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	99.28	gold quality
blood	UBERON:0000178	98.60	gold quality
ganglionic eminence	UBERON:0004023	98.12	gold quality
right lobe of thyroid gland	UBERON:0001119	98.00	gold quality
left lobe of thyroid gland	UBERON:0001120	97.63	gold quality
granulocyte	CL:0000094	97.07	gold quality
thymus	UBERON:0002370	96.97	gold quality
bone marrow	UBERON:0002371	96.77	gold quality
spleen	UBERON:0002106	96.24	gold quality
thyroid gland	UBERON:0002046	96.23	gold quality
vermiform appendix	UBERON:0001154	96.21	gold quality
leukocyte	CL:0000738	96.15	gold quality
mononuclear cell	CL:0000842	96.03	gold quality
monocyte	CL:0000576	96.02	gold quality
lymph node	UBERON:0000029	95.99	gold quality
bone marrow cell	CL:0002092	95.55	gold quality
right lung	UBERON:0002167	95.34	gold quality
trabecular bone tissue	UBERON:0002483	95.15	gold quality
caecum	UBERON:0001153	94.06	gold quality
ileal mucosa	UBERON:0000331	93.84	gold quality
lower lobe of lung	UBERON:0008949	92.88	gold quality
upper lobe of left lung	UBERON:0008952	91.54	gold quality
superficial temporal artery	UBERON:0001614	91.29	gold quality
upper lobe of lung	UBERON:0008948	91.28	gold quality
pericardium	UBERON:0002407	91.27	gold quality
lung	UBERON:0002048	90.05	gold quality
periodontal ligament	UBERON:0008266	89.86	gold quality
embryo	UBERON:0000922	89.36	gold quality
gall bladder	UBERON:0002110	88.40	gold quality
pylorus	UBERON:0001166	87.16	gold quality

Single-cell (SCXA)

Detected in 13 experiment(s), a significant marker in 11.

Experiment	Marker?	Max mean expression
E-GEOD-106540	yes	2639.05
E-HCAD-5	yes	70.03
E-GEOD-135922	yes	38.57
E-MTAB-10287	yes	32.28
E-HCAD-1	yes	29.71
E-MTAB-8410	yes	27.46
E-MTAB-6678	yes	26.38
E-CURD-46	yes	16.07
E-HCAD-10	yes	7.28
E-CURD-119	yes	6.50
E-GEOD-70580	no	2426.05
E-CURD-112	no	3.27
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, HR, MYC

miRNA regulators (miRDB)

72 targeting SLA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-6892-3P	99.68	66.40	1178
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-6126	99.62	68.09	996
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-3123	99.47	67.15	2693

Literature-anchored findings (GeneRIF, showing 7)

• The SLA molecule and its functionally relevant residues have been highly conserved throughout the evolution. (PMID:16521218)
• Although SLA is a prominent glucocorticoids response gene, it does not seem to contribute to the anti-leukemic effects of glucocorticoids. (PMID:19631983)
• These data provide evidence for src-like adaptor protein-dependent regulation of CD3 zeta-chain in the fine control of TCR signaling. (PMID:22798681)
• upon ligand stimulation SLAP stably associates with Flt3 through multiple phosphotyrosine residues in Flt3. SLAP mRNA is differentially expressed in different cancers and its expression significantly increased in patients carrying the Flt3-ITD mutation (PMID:23300935)
• Taken together the data demonstrate that SLAP negatively regulates wild-type c-Kit signaling, but not its oncogenic counterpart, indicating a possible mechanism by which the oncogenic c-Kit bypasses the normal cellular negative feedback control (PMID:24284075)
• results suggest that cytoplasm-specific transduction of the SH3 and SH2 domains of SLAP has a therapeutic potential of being an immunosuppressive reagent for the treatment of various autoimmune diseases (PMID:25800872)
• SLAP Is a Negative Regulator of FcepsilonRI Receptor-Mediated Signaling and Allergic Response. (PMID:31156621)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	sla1a	ENSDARG00000054340
danio_rerio	SLA	ENSDARG00000100287
mus_musculus	Sla	ENSMUSG00000022372
rattus_norvegicus	Sla	ENSRNOG00000056714
drosophila_melanogaster	dock	FBGN0010583
caenorhabditis_elegans		WBGENE00006410

Paralogs (9): DAPP1 (ENSG00000070190), NCK2 (ENSG00000071051), GRAP2 (ENSG00000100351), SLA2 (ENSG00000101082), GRAP (ENSG00000154016), NCK1 (ENSG00000158092), GRB2 (ENSG00000177885), GRAPL (ENSG00000189152), SH2D5 (ENSG00000189410)

Protein

Protein identifiers

Src-like-adapter — Q13239 (reviewed: Q13239)

Alternative names: Src-like-adapter protein 1

All UniProt accessions (8): Q13239, E5RGG0, E5RH80, E5RHT2, E5RJ69, E5RJB0, E5RK29, E5RK95

UniProt curated annotations — full annotation on UniProt →

Function. Adapter protein, which negatively regulates T-cell receptor (TCR) signaling. Inhibits T-cell antigen-receptor induced activation of nuclear factor of activated T-cells. Involved in the negative regulation of positive selection and mitosis of T-cells. May act by linking signaling proteins such as ZAP70 with CBL, leading to a CBL dependent degradation of signaling proteins.

Subunit / interactions. Interacts with EPHA2, VAV1, LCP2 and PDGFRB. Homodimer. Homodimerization and interaction with phosphorylated CBL occurs via its C-terminal domain. Interacts with phosphorylated proteins ZAP70, CD3Z, SYK and LAT via its SH2 domain.

Subcellular location. Cytoplasm. Endosome.

Tissue specificity. Expressed in lung and fetal brain. Weakly expressed in heart, adult brain, placenta, liver, skeletal muscle, kidney and pancreas.

Domain organisation. The C-terminal domain is essential for the homodimerization and the interaction with CBL. While the interaction with CBL is apparently mediated via the hydrophobic region of this domain, the highly charged region is apparently required for the homodimerization.

Induction. By all-trans retinoic acid (ATRA). Induction is indirect and is mediated through other proteins.

Isoforms (5)

UniProt ID	Names	Canonical?
Q13239-1	1	yes
Q13239-2	2
Q13239-3	3
Q13239-4	4
Q13239-5	5

RefSeq proteins (5): NP_001039021, NP_001039022, NP_001269893, NP_001269894, NP_006739 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000980	SH2	Domain
IPR001452	SH3_domain	Domain
IPR035052	SLAP_SH2	Domain
IPR035596	SLAP_SH3	Domain
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR036860	SH2_dom_sf	Homologous_superfamily
IPR043539	Grb2-like	Family

Pfam: PF00017, PF00018

UniProt features (28 total): strand 6, mutagenesis site 5, splice variant 4, domain 2, turn 2, modified residue 2, initiator methionine 1, chain 1, sequence variant 1, sequence conflict 1, helix 1, region of interest 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2CUD	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13239-F1	75.16	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 253, 273, 2

Mutagenesis-validated functional residues (5):

Position	Phenotype
111	strongly reduces interaction with zap70, cd3z, syk and lat.
218	abolishes interaction with cbl. does not affect dimerization; when associated with s-224 and s-229.
224	abolishes interaction with cbl. does not affect dimerization; when associated with s-218 and s-229.
229	abolishes interaction with cbl. does not affect dimerization; when associated with s-218 and s-224.
237–239	abolishes interaction with cbl. slightly affects dimerization.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-9706369	Negative regulation of FLT3
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-168256	Immune System
R-HSA-9607240	FLT3 Signaling

MSigDB gene sets: 302 (showing top): WALLACE_PROSTATE_CANCER_RACE_UP, MCLACHLAN_DENTAL_CARIES_UP, LU_IL4_SIGNALING, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, RORA1_01, MODULE_45, MODULE_64, MODULE_16, SHIPP_DLBCL_CURED_VS_FATAL_DN, MODULE_118, GNF2_ICAM3, AML_Q6, OCT1_07, MODULE_157, CLIMENT_BREAST_CANCER_COPY_NUMBER_UP

GO Biological Process (2): signal transduction (GO:0007165), regulation of MAPK cascade (GO:0043408)

GO Molecular Function (3): phosphotyrosine residue binding (GO:0001784), epidermal growth factor receptor binding (GO:0005154), protein binding (GO:0005515)

GO Cellular Component (6): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), endosome (GO:0005768), cytosol (GO:0005829), plasma membrane (GO:0005886), COP9 signalosome (GO:0008180)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
FLT3 Signaling	1
Immune System	1
Cytokine Signaling in Immune system	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
MAPK cascade	1
regulation of intracellular signal transduction	1
protein phosphorylated amino acid binding	1
growth factor receptor binding	1
binding	1
nuclear lumen	1
intracellular anatomical structure	1
endomembrane system	1
cytoplasmic vesicle	1
cytoplasm	1
membrane	1
cell periphery	1
nuclear protein-containing complex	1

Protein interactions and networks

STRING

1978 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLA	SLMAP	Q14BN4	896
SLA	NLRP2	Q9NX02	846
SLA	ITSN1	Q15811	592
SLA	EPS15	P42566	587
SLA	RPL13	P26373	495
SLA	DNM1L	O00429	491
SLA	ACTA1	P02568	481
SLA	SAAL1	Q96ER3	475
SLA	CBL	P22681	455
SLA	RCC1	P18754	442
SLA	CD8A	P01732	438
SLA	TG	P01266	435
SLA	CLCN1	P35523	424
SLA	FLT3	P36888	416
SLA	MYO5A	Q9Y4I1	401

IntAct

20 interactions, top by confidence:

A	B	Type	Score
EGFR	SLA	psi-mi:“MI:0915”(physical association)	0.690
SLA	EGFR	psi-mi:“MI:0407”(direct interaction)	0.690
SLA	NCOA2	psi-mi:“MI:0915”(physical association)	0.590
SLA	PDGFRB	psi-mi:“MI:0914”(association)	0.460
SLA	ERBB2	psi-mi:“MI:0407”(direct interaction)	0.440
SLA	GAB1	psi-mi:“MI:0407”(direct interaction)	0.440
ECE1	SLA	psi-mi:“MI:0915”(physical association)	0.370
ALK	SLA	psi-mi:“MI:0915”(physical association)	0.370
SLA	GSK3B	psi-mi:“MI:0915”(physical association)	0.370
CUL4A	HAX1	psi-mi:“MI:0914”(association)	0.350
SLA	Ptpn6	psi-mi:“MI:0914”(association)	0.350
SLA	TIMM50	psi-mi:“MI:0915”(physical association)	0.000
PAFAH1B2	SLA	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (41): SLA (Two-hybrid), SLA (PCA), SLA (Affinity Capture-MS), SLA (Two-hybrid), NCOA2 (Affinity Capture-MS), SLA (Two-hybrid), SLA (Two-hybrid), SLA (Two-hybrid), QARS (Two-hybrid), MYO15B (Two-hybrid), ZAP70 (Affinity Capture-Western), CD247 (Affinity Capture-Western), SYK (Affinity Capture-Western), LAT (Affinity Capture-Western), SLA (Reconstituted Complex)

ESM2 similar proteins: B2RZ59, F1LYQ8, F1P065, F8VPU2, O14796, O35324, O60880, O75791, O88890, O88900, O89100, O94887, P0CE43, P46108, P46109, P47941, P52735, P59622, P87378, P97369, Q03160, Q04929, Q06AA1, Q13239, Q13322, Q14449, Q15080, Q1RMW5, Q2I6J1, Q3ZBB1, Q45HK4, Q5ICW4, Q5RAB8, Q5U2U2, Q60760, Q60898, Q60992, Q63768, Q64010, Q6P4S2

Diamond homologs: A0JNB0, A1A5H8, A1Y2K1, A6QLK6, F1LM93, F1RDG9, O01498, O43639, O45539, O55033, O75791, O75886, O88811, O89100, O93436, P00519, P00520, P00522, P00527, P00528, P03949, P06239, P06240, P06241, P07947, P07948, P08103, P08631, P09324, P09769, P10447, P10569, P10936, P13406, P14234, P16277, P17713, P25911, P27446, P27447

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
SLA	“down-regulates quantity by destabilization”	EPHA2	binding
KIT	“down-regulates activity”	SLA	phosphorylation
SLA	“down-regulates quantity by destabilization”	KIT	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

150 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	6
Likely pathogenic	2
Uncertain significance	67
Likely benign	46
Benign	7

Top pathogenic / likely-pathogenic (8)

Variant ID	HGVS	Classification
2710858	NM_003235.5(TG):c.7342C>T (p.Gln2448Ter)	Pathogenic
2847414	NM_003235.5(TG):c.7277del (p.His2426fs)	Pathogenic
2967695	NM_003235.5(TG):c.7332_7333del (p.Met2444fs)	Pathogenic
3633212	NM_003235.5(TG):c.7276_7277insT (p.His2426fs)	Pathogenic
3693483	NM_003235.5(TG):c.7326C>A (p.Cys2442Ter)	Pathogenic
3896375	NM_003235.5(TG):c.7502G>A (p.Trp2501Ter)	Pathogenic
3618494	NM_003235.5(TG):c.7572+2T>C	Likely pathogenic
3672100	NM_003235.5(TG):c.7404+1G>A	Likely pathogenic

SpliceAI

2909 predictions. Top by Δscore:

Variant	Effect	Δscore
8:133038746:C:CT	acceptor_gain	1.0000
8:133039995:CAC:C	donor_loss	1.0000
8:133039996:A:AC	donor_gain	1.0000
8:133039997:C:CC	donor_gain	1.0000
8:133039997:C:CT	donor_loss	1.0000
8:133040126:CACCT:C	acceptor_gain	1.0000
8:133040129:CT:C	acceptor_gain	1.0000
8:133040131:C:CC	acceptor_gain	1.0000
8:133047828:A:AC	donor_gain	1.0000
8:133047828:AC:A	donor_gain	1.0000
8:133047829:C:CC	donor_gain	1.0000
8:133047829:C:CG	donor_loss	1.0000
8:133047829:CC:C	donor_gain	1.0000
8:133047829:CCT:C	donor_gain	1.0000
8:133047829:CCTTT:C	donor_gain	1.0000
8:133047929:GCCAG:G	acceptor_gain	1.0000
8:133047930:CCAG:C	acceptor_gain	1.0000
8:133047930:CCAGC:C	acceptor_gain	1.0000
8:133047931:CAG:C	acceptor_gain	1.0000
8:133047931:CAGC:C	acceptor_gain	1.0000
8:133047932:AG:A	acceptor_gain	1.0000
8:133047932:AGCT:A	acceptor_loss	1.0000
8:133047933:GC:G	acceptor_loss	1.0000
8:133047934:C:CC	acceptor_gain	1.0000
8:133047934:CTGG:C	acceptor_loss	1.0000
8:133049896:ACTC:A	donor_loss	1.0000
8:133049897:CTC:C	donor_loss	1.0000
8:133049898:TCA:T	donor_loss	1.0000
8:133049899:CACC:C	donor_loss	1.0000
8:133049900:A:AC	donor_gain	1.0000

AlphaMissense

1788 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:133040103:A:T	L171H	1.000
8:133045001:A:G	L156P	1.000
8:133045018:G:C	F150L	1.000
8:133045018:G:T	F150L	1.000
8:133045019:A:G	F150S	1.000
8:133045020:A:G	F150L	1.000
8:133045037:A:T	I144N	1.000
8:133045067:A:C	I134S	1.000
8:133045067:A:G	I134T	1.000
8:133045067:A:T	I134N	1.000
8:133045074:A:C	Y132D	1.000
8:133045075:A:C	H131Q	1.000
8:133045075:A:T	H131Q	1.000
8:133045077:G:C	H131D	1.000
8:133045103:A:G	L122P	1.000
8:133047849:T:A	R111S	1.000
8:133047849:T:G	R111S	1.000
8:133047850:C:A	R111I	1.000
8:133047850:C:G	R111T	1.000
8:133047851:T:C	R111G	1.000
8:133047853:A:T	I110N	1.000
8:133047858:G:C	F108L	1.000
8:133047858:G:T	F108L	1.000
8:133047859:A:G	F108S	1.000
8:133047860:A:G	F108L	1.000
8:133047865:C:T	G106D	1.000
8:133047889:A:G	L98P	1.000
8:133047892:A:G	L97P	1.000
8:133047928:A:G	L85P	1.000
8:133047932:A:G	W84R	1.000

dbSNP variants (sampled 300 via entrez): RS1000116559 (8:133039572 T>G), RS1000123975 (8:133063607 G>A), RS1000196456 (8:133086657 A>G), RS1000232383 (8:133060902 T>C), RS1000263 (8:133097532 C>G), RS1000264 (8:133098034 A>G), RS1000307885 (8:133086449 ATTC>A), RS1000357482 (8:133065771 T>C), RS1000358340 (8:133075360 CTTCT>C), RS1000419361 (8:133042542 C>T), RS1000444694 (8:133092192 C>G), RS1000453793 (8:133042895 T>C), RS1000543172 (8:133086989 A>C), RS1000547849 (8:133077021 T>C), RS1000642053 (8:133080938 A>G)

Disease associations

OMIM: gene MIM:601099 | disease phenotypes: MIM:274700, MIM:608175

GenCC curated gene-disease

Mondo (2): thyroid dyshormonogenesis 3 (MONDO:0010135), autoimmune thyroid disease, susceptibility to, 3 (MONDO:0011982)

Orphanet (1): Familial thyroid dyshormonogenesis (Orphanet:95716)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C562769	Thyroid Dyshormonogenesis 3 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tretinoin	affects cotreatment, decreases reaction, increases expression	5
Benzo(a)pyrene	affects methylation, decreases expression	3
Estradiol	affects cotreatment, increases expression	2
Valproic Acid	affects expression, increases methylation	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
pyrimidin-2-one beta-ribofuranoside	increases expression	1
butyraldehyde	increases expression	1
pyrrolidine dithiocarbamic acid	increases expression, affects cotreatment, decreases reaction	1
bathocuproine sulfonate	affects cotreatment, decreases reaction, increases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression, affects cotreatment	1
tamibarotene	increases expression	1
tebuconazole	increases expression	1
cylindrospermopsin	increases expression	1
CGP 52608	affects binding, increases reaction	1
nickel acetate	affects expression	1
2,2’,4,4’,5-brominated diphenyl ether	decreases expression	1
abrine	increases expression	1
Decitabine	increases expression	1
Arsenic Trioxide	affects cotreatment, increases expression	1
Norethindrone Acetate	affects cotreatment, increases expression	1
Acetaminophen	decreases expression	1
Calcitriol	decreases expression	1
Cisplatin	increases expression	1
Cycloheximide	decreases reaction, increases expression	1
Cytarabine	increases expression	1
Dexamethasone	increases expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Nickel	increases expression	1

Clinical trials (associated diseases)

1 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03655223	Not specified	ENROLLING_BY_INVITATION	Early Check: Expanded Screening in Newborns